Valneva jumps after deal to provide chikungunya vaccine
** Shares in Valneva VLS.PA jump around 7% after the French vaccine company said it will provide 40,000 doses of chikungunya shots in France's Island of La Réunion ** Broker Portzamparc estimates the contract is valued at 3.5 million euros ** They note that the ongoing outbreak on the island has elevated the IXCHIQ vaccine to "public utility" status ** Up to the previous session's close, shares were up 56.6% YTD (Reporting by Johan Bodinier) ((johangeorgesroger.bodinier@thomsonreuters.com))
Recent news on Valneva SE
See all newsBrief: UK MHRA Withdraws Marketing Authorisation for Ixchiq Chikungunya Vaccine After Safety Review
Valneva falls as UK regulator revokes Ixchiq vaccine authorisation
Brief: Valneva Provides Update On Ixchiq® In The United Kingdom
Valneva surges after EU regulator validates Lyme disease vaccine application
Brief: Pfizer And Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated By European Medicines Agency